Tumor-intrinsic RGS1 potentiates checkpoint blockade response via ATF3-IFNGR1 axis

References

• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–13. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non–small-Cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. doi:10.1056/NEJMoa1501824.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–829. doi:10.1056/NEJMoa1604958.
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201. doi:10.1158/2159-8290.CD-16-1223.
   PubMed Web of Science ®Google Scholar
• Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413–418. doi:10.1038/nature23270.
   PubMed Web of Science ®Google Scholar
• Jia H, Song L, Cong Q, Wang J, Xu H, Chu Y, Li Q, Zhang Y, Zou X, Zhang C, et al. The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network. Oncogene. 2017;36(19):2655–2666. doi:10.1038/onc.2016.418.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Peng D, Kryczek I, Wu K, Li W, Zhao E, Zhao L, Wei S, Frankel T, Vatan L, et al. PRC2 epigenetically silences Th1-type chemokines to suppress effector T-Cell trafficking in colon cancer. Cancer Res. 2016;76(2):275–282. doi:10.1158/0008-5472.CAN-15-1938.
   PubMed Web of Science ®Google Scholar
• Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249–253. doi:10.1038/nature15520.
   PubMed Web of Science ®Google Scholar
• Du W, Hua F, Li X, Zhang J, Li S, Wang W, Zhou J, Wang W, Liao P, Yan Y, et al. Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation. Cancer Discov. 2021;11(7):1826–1843. doi:10.1158/2159-8290.CD-20-1571.
   PubMed Web of Science ®Google Scholar
• Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020;11(1):2135. doi:10.1038/s41467-020-15959-6.
   PubMed Web of Science ®Google Scholar
• Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, et al. FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells. Cell. 2021;184(2):352–369.e23. doi:10.1016/j.cell.2020.11.042.
   PubMed Web of Science ®Google Scholar
• Ren J, Li N, Pei S, Lian Y, Li L, Peng Y, Liu Q, Guo J, Wang X, Han Y, et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ–stimulated antitumor immunity. Journal Of Clinical Investigation. 2022;132(8). doi:10.1172/JCI153167.
   Web of Science ®Google Scholar
• Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, Xie L, Huang Q, Li F, Li C-Y, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588(7839):693–698. doi:10.1038/s41586-020-2911-7.
   PubMed Web of Science ®Google Scholar
• Watson N, Linder ME, Druey KM, Kehrl JH, Blumer KJ. RGS family members: GTPase-activating proteins for heterotrimeric G-protein α-subunits. Nature. 1996;383(6596):172–175. doi:10.1038/383172a0.
   PubMed Web of Science ®Google Scholar
• Huang D, Chen X, Zeng X, Lao L, Li J, Xing Y, Lu Y, Ouyang Q, Chen J, Yang L, et al. Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer. Nat Immunol. 2021;22(7):865–879. doi:10.1038/s41590-021-00939-9.
   PubMed Web of Science ®Google Scholar
• Bai Y, Hu M, Chen Z, Wei J, Du H. Single-cell transcriptome analysis reveals RGS1 as a New Marker and promoting factor for T-Cell exhaustion in multiple cancers. Front Immunol. 2021;12:767070. doi:10.3389/fimmu.2021.767070.
   PubMed Web of Science ®Google Scholar
• Burr ML, Sparbier CE, Chan KL, Chan Y-C, Kersbergen A, Lam EYN, Azidis-Yates E, Vassiliadis D, Bell CC, Gilan O, et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36(4):385–401.e8. doi:10.1016/j.ccell.2019.08.008.
   PubMed Web of Science ®Google Scholar
• Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, Xie Z, Weng L, Guo J, Li H, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis. Cancer Cell. 2020;37(3):324–339.e8. doi:10.1016/j.ccell.2020.02.006.
   PubMed Web of Science ®Google Scholar
• Li G, Kryczek I, Nam J, Li X, Li S, Li J, Wei S, Grove S, Vatan L, Zhou J, et al. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol. 2021;23(5):526–537. doi:10.1038/s41556-021-00672-3.
   PubMed Web of Science ®Google Scholar
• Weisshaar N, Wu J, Ming Y, Madi A, Hotz-Wagenblatt A, Ma S, Mieg A, Hering M, Zettl F, Mohr K, et al. Rgs16 promotes antitumor CD8+T cell exhaustion. Sci Immunol. 2022;7(71):eabh1873. doi:10.1126/sciimmunol.abh1873.
   PubMed Web of Science ®Google Scholar
• Zhou F. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol. 2009;28(3–4):239–260. doi:10.1080/08830180902978120.
   PubMed Web of Science ®Google Scholar
• Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, Yuan J, Rana TM. m6A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020;39(20):e104514. doi:10.15252/embj.2020104514.
   PubMed Web of Science ®Google Scholar
• Ross EM, Wilkie TM. Gtpase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem. 2000;69(1):795–827. doi:10.1146/annurev.biochem.69.1.795.
   PubMedGoogle Scholar
• De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2014;15(2):152–160. doi:10.1038/ni.2784.
   PubMed Web of Science ®Google Scholar
• Kim JY, Song EH, Lee S, Lim JH, Choi JS, Koh I-U, Song J, Kim W-H. The induction of STAT1 gene by activating transcription factor 3 contributes to pancreatic β-cell apoptosis and its dysfunction in streptozotocin-treated mice. Cell Signal. 2010;22(11):1669–1680. doi:10.1016/j.cellsig.2010.06.007.
   PubMed Web of Science ®Google Scholar
• Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, Xu B, Ye D, Nathanson KL, June CH, et al. Opposing functions of interferon Coordinate Adaptive and innate immune responses to cancer immune checkpoint blockade. Cell. 2019;178(4):933–948.e14. doi:10.1016/j.cell.2019.07.019.
   PubMed Web of Science ®Google Scholar
• Guo W, Wang Y, Yang M, Wang Z, Wang Y, Chaurasia S, Wu Z, Zhang M, Yadav GS, Rathod S, et al. LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. Sci Adv. 2021;7(7):eabb3555. doi:10.1126/sciadv.abb3555.
   PubMed Web of Science ®Google Scholar
• Sun MY, Wang Y, Zhu J, Lv C, Wu K, Wang X, Xue C. Critical role for non‑GAP function of Gαs in RGS1‑mediated promotion of melanoma progression through AKT and ERK phosphorylation. Oncol Rep. 2018;39(6):2673–2680. doi:10.3892/or.2018.6341.
   PubMed Web of Science ®Google Scholar
• Dai J, Gu J, Lu C, Lin J, Stewart D, Chang D, Roth JA, Wu X. Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PloS One. 2011;6(6):e21120. doi:10.1371/journal.pone.0021120.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zheng M, Wang S, Gao L, Gou R, Liu O, Dong H, Li X, Lin B. Identification of a five-gene signature of the RGS gene family with prognostic value in ovarian cancer. Genomics. 2021;113(4):2134–2144. doi:10.1016/j.ygeno.2021.04.012.
   PubMed Web of Science ®Google Scholar
• Roh J, Shin S-J, Lee A-N, Yoon DH, Suh C, Park C-J, Huh J, Park C-S. RGS1 expression is associated with poor prognosis in multiple myeloma. J Clin Pathol. 2017;70(3):202–207. doi:10.1136/jclinpath-2016-203713.
   PubMed Web of Science ®Google Scholar
• Li M, Xu Y, Liang J, Lin H, Qi X, Li F, Han P, Gao Y, Yang X. USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis. Mol Ther. 2021;29(6):2108–2120. doi:10.1016/j.ymthe.2021.02.018.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar S, Srivastava RK, Nandi A, Thacker G, Murali H, Kim S, Baldeon M, Tobias J, Blanco MA, et al. Loss of ELF5–FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling. Nat Cell Biol. 2020;22(5):591–602. doi:10.1038/s41556-020-0495-y.
   PubMed Web of Science ®Google Scholar